Discounted Cash Flow (DCF) Analysis Unlevered
AVITA Medical, Inc. (RCEL)
$13.21
-0.17 (-1.27%)
All numbers are in Millions, Currency in USD
Operating Data
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
Revenue | 0.88 | 5.40 | 14.26 | 29.23 | 34.42 | 103.24 | 309.67 | 928.82 | 2,785.91 | 8,356.10 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue (%) | ||||||||||
EBITDA | -13.03 | -24.46 | -41.53 | -25.81 | -26.33 | -493.19 | -1,479.27 | -4,436.93 | -13,308.18 | -39,916.71 |
EBITDA (%) | ||||||||||
EBIT | -13.13 | -24.72 | -41.99 | -26.52 | -26.61 | -498.02 | -1,493.77 | -4,480.44 | -13,438.67 | -40,308.10 |
EBIT (%) | ||||||||||
Depreciation | 0.11 | 0.26 | 0.47 | 0.72 | 0.29 | 4.84 | 14.50 | 43.50 | 130.49 | 391.39 |
Depreciation (%) |
Balance Sheet Data
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
Total Cash | 10.89 | 20.30 | 73.64 | 110.75 | 79.34 | 565.45 | 1,696.01 | 5,087.02 | 15,258.05 | 45,765.17 |
---|---|---|---|---|---|---|---|---|---|---|
Total Cash (%) | ||||||||||
Account Receivables | 3.99 | 2.09 | 2.43 | 7.88 | 3.51 | 112.83 | 338.43 | 1,015.11 | 3,044.72 | 9,132.36 |
Account Receivables (%) | ||||||||||
Inventories | 0.85 | 0.74 | 1.12 | 1.65 | 2.13 | 26.81 | 80.41 | 241.18 | 723.41 | 2,169.80 |
Inventories (%) | ||||||||||
Accounts Payable | 0.20 | 0.48 | 4.33 | 3.12 | 6.24 | 18.72 | 56.16 | 168.46 | 505.27 | 1,515.52 |
Accounts Payable (%) | ||||||||||
Capital Expenditure | -0.37 | -1.26 | -0.85 | -1.17 | -0.45 | -15.73 | -47.17 | -141.48 | -424.35 | -1,272.80 |
Capital Expenditure (%) |
Weighted Average Cost Of Capital
Share price | $ 13.21 |
---|---|
Beta | 0.969 |
Diluted Shares Outstanding | 22.67 |
Cost of Debt | |
Tax Rate | -0.14 |
After-tax Cost of Debt | 5.23% |
Risk-Free Rate | |
Market Risk Premium | |
Cost of Equity | 8.057 |
Total Debt | 0.31 |
Total Equity | 299.53 |
Total Capital | 299.83 |
Debt Weighting | 0.10 |
Equity Weighting | 99.90 |
Wacc |
Build Up Free Cash
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
Revenue | 0.88 | 5.40 | 14.26 | 29.23 | 34.42 | 103.24 | 309.67 | 928.82 | 2,785.91 | 8,356.10 |
---|---|---|---|---|---|---|---|---|---|---|
EBITDA | -13.03 | -24.46 | -41.53 | -25.81 | -26.33 | -493.19 | -1,479.27 | -4,436.93 | -13,308.18 | -39,916.71 |
EBIT | -13.13 | -24.72 | -41.99 | -26.52 | -26.61 | -498.02 | -1,493.77 | -4,480.44 | -13,438.67 | -40,308.10 |
Tax Rate | 7.74% | 0.51% | -0.01% | -0.14% | -0.14% | 1.59% | 1.59% | 1.59% | 1.59% | 1.59% |
EBIAT | -12.12 | -24.60 | -42 | -26.56 | -26.65 | -490.09 | -1,469.99 | -4,409.10 | -13,224.70 | -39,666.32 |
Depreciation | 0.11 | 0.26 | 0.47 | 0.72 | 0.29 | 4.84 | 14.50 | 43.50 | 130.49 | 391.39 |
Accounts Receivable | - | 1.91 | -0.34 | -5.45 | 4.37 | -109.32 | -225.60 | -676.67 | -2,029.61 | -6,087.64 |
Inventories | - | 0.11 | -0.38 | -0.52 | -0.48 | -24.68 | -53.60 | -160.77 | -482.22 | -1,446.39 |
Accounts Payable | - | 0.28 | 3.86 | -1.21 | 3.12 | 12.48 | 37.44 | 112.29 | 336.82 | 1,010.25 |
Capital Expenditure | -0.37 | -1.26 | -0.85 | -1.17 | -0.45 | -15.73 | -47.17 | -141.48 | -424.35 | -1,272.80 |
UFCF | -12.38 | -23.30 | -39.25 | -34.21 | -19.80 | -622.50 | -1,744.42 | -5,232.22 | -15,693.59 | -47,071.52 |
WACC | ||||||||||
PV UFCF | -576.13 | -1,494.17 | -4,147.74 | -11,513.92 | -31,962.03 | |||||
SUM PV UFCF | -49,693.99 |
Terminal Value
Growth in perpetuity method: | |
---|---|
Long-term growth rate | |
WACC (%) | 8.05 |
Free cash flow (t + 1) | -48,012.95 |
Terminal Value | -793,602.53 |
Present Value of Terminal Value | -538,864.02 |
Intrinsic Value
Enterprise Value | -588,558.01 |
---|---|
Net Debt | -17.86 |
Equity Value | -588,540.16 |
Shares Outstanding | 22.67 |
Equity Value Per Share | -25,956.25 |